Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell AbbVie Inc (ABBV) – AbbVie Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

AbbVie (ABBV) trades at $213.22, up 1.84% on the day, with technical indicators signaling a bearish trend amid recent price consolidation. The stock shows strong earnings beats in recent quarters, with Q2-Q4 2025 EPS exceeding expectations, while Q1 2026 is projected at $3.01. Key fundamentals include a high P/E ratio of 91.77 and a net income margin of 6.91%, supported by robust revenue growth projections for 2026 driven by Skyrizi and Rinvoq.
The outlook remains positive with a consensus price target of $256.50, reflecting a 20% upside, though risks include elevated debt levels and competitive pressures. Institutional sentiment is bullish, with 67.5% of analysts rating it a buy, but investors should monitor cash flow trends and regulatory developments.
Read full analysis

Key Stats

  • Market Cap
    $384.69B
  • Sector
    Health
  • 3M Drawdown
    -13.24%
  • Enterprise Value
    $446.93B
  • Dividend Yield
    3.18%
  • Typical Hold Time
    90 days
$217.25
52W Low: $170.16
21 Apr 2025
52W High: $244.38
01 Oct 2025

AbbVie Inc (ABBV) is currently valued at a market capitalization of $384.69B, with an enterprise value of $446.93B. Over the past 52 weeks, AbbVie Inc has traded between a low of $170.16 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -13.24%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.18%, with the most recent dividend of $1.73 paid on 16 Jan 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.


Technical Indicators
|
|
|
Overall Summary
Bearish (6)Neutral (7)Bullish (14)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $384.69B
  • Sector
    Health
  • 3M Drawdown
    -13.24%
  • Enterprise Value
    $446.93B
  • Dividend Yield
    3.18%
  • Typical Hold Time
    90 days
$217.25
52W Low: $170.16
21 Apr 2025
52W High: $244.38
01 Oct 2025

AbbVie Inc (ABBV) is currently valued at a market capitalization of $384.69B, with an enterprise value of $446.93B. Over the past 52 weeks, AbbVie Inc has traded between a low of $170.16 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -13.24%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.18%, with the most recent dividend of $1.73 paid on 16 Jan 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!